These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2133 related items for PubMed ID: 26147946

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM.
    JAMA Neurol; 2016 May 01; 73(5):561-71. PubMed ID: 27018940
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 01; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 5. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TLS, Fagan AM, Morris JC, Roe CM.
    Am J Geriatr Psychiatry; 2016 Nov 01; 24(11):1095-1104. PubMed ID: 27426238
    [Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM.
    Alzheimers Res Ther; 2015 Sep 17; 7(1):59. PubMed ID: 26383836
    [Abstract] [Full Text] [Related]

  • 7. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
    Alcolea D, Martínez-Lage P, Sánchez-Juan P, Olazarán J, Antúnez C, Izagirre A, Ecay-Torres M, Estanga A, Clerigué M, Guisasola MC, Sánchez Ruiz D, Marín Muñoz J, Calero M, Blesa R, Clarimón J, Carmona-Iragui M, Morenas-Rodríguez E, Rodríguez-Rodríguez E, Vázquez Higuera JL, Fortea J, Lleó A.
    Neurology; 2015 Aug 18; 85(7):626-33. PubMed ID: 26180139
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
    Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J, Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
    JAMA Neurol; 2018 May 01; 75(5):608-619. PubMed ID: 29482212
    [Abstract] [Full Text] [Related]

  • 13. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM.
    Ann Neurol; 2016 Sep 01; 80(3):379-87. PubMed ID: 27398953
    [Abstract] [Full Text] [Related]

  • 14. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, Giau VV, Bagyinszky E, Lim KT, Kang SM, An SS, Park YH, Youn YC, Kim S.
    J Alzheimers Dis; 2016 May 06; 52(4):1403-13. PubMed ID: 27163824
    [Abstract] [Full Text] [Related]

  • 15. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
    Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM.
    JAMA Neurol; 2014 Jul 01; 71(7):855-62. PubMed ID: 24818585
    [Abstract] [Full Text] [Related]

  • 16. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
    Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C.
    JAMA Neurol; 2019 Mar 01; 76(3):264-273. PubMed ID: 30615028
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.
    Biol Psychiatry; 2010 Nov 15; 68(10):903-12. PubMed ID: 21035623
    [Abstract] [Full Text] [Related]

  • 20. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S, AIBL Research Group.
    J Alzheimers Dis; 2015 Nov 15; 48(1):175-87. PubMed ID: 26401938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 107.